References
Makri OE, Georgalas I, Georgakopoulos CD (2013) Drug-induced macular edema. Drugs 73:789–802
Saenz-de-Viteri M, Cudrnak M (2019) Bilateral cystoid macular edema in a patient with chronic lymphocytic leukemia treated withibrutinib. LeukLymphoma 60(3):842–844
Farooqui MZH, Valdez J, Martyr S et al (2015) Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial. Lancet Oncol 16:169–176
Bernard S, Goldwirt L, Amorim S et al (2015) Activity of ibrutinib in mantle cell lymphoma patients with central nervous systemrelapse. Blood 126:1695–1698
Byrd JC, Brown JR, O’Brien S, Barrientos JC, Kay NE, Reddy NM, Coutre S et al (2014) Ibrutinib versus ofatumumab in previously treated chronic lymphocytic leukemia. N Engl J Med 371:213–223
Shaikh H, Khattab A, Faisal MS, Chilkulwar A, Albrethsen M, Sadashiv S, Fazal S (2018) Case series of unique adverse events related to the use of ibrutinib in patients with B-cell malignancies—a single institution experience and a review of literature. J Oncol Pharm Pract 25:1078155218788707
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Mirgh, S.P., Ahmed, R., Agrawal, N. et al. Knowing the Flip Side of the Coin: Ibrutinib Associated Cystoid Macular Edema. Indian J Hematol Blood Transfus 36, 208–210 (2020). https://doi.org/10.1007/s12288-019-01181-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12288-019-01181-y